Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 566 publications
Efficacy and Safety of Antibody Drug Conjugates in Previously Treated Hormone Receptor Positive HER2 Negative (or Low) Metastatic Breast Cancer-A Systematic Review and Meta-Analysis.
Journal: American journal of clinical oncology
Published: October 14, 2025
A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy.
Journal: Future oncology (London, England)
Published: September 01, 2025
Recent advances in antibody-drug conjugates for metastatic castration-resistant prostate cancer.
Journal: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
Published: August 27, 2025
Antibody-drug conjugates in the treatment of advanced triple-negative breast cancer.
Journal: Przeglad menopauzalny = Menopause review
Published: August 24, 2025
Antibody-drug conjugates in breast cancer: From therapeutic and immune activation mechanisms to resistance prevention.
Journal: International reviews of immunology
Published: August 19, 2025
Real-world disproportionality analysis of cardiac failure associated with novel antineoplastic agents in breast cancer: a pharmacovigilance study.
Journal: Frontiers in immunology
Published: August 06, 2025
Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report.
Journal: Journal of neuro-oncology
Published: July 31, 2025
Penile carcinoma: the importance of histological classification and new treatment strategies
Journal: Aktuelle Urologie
Published: July 28, 2025
Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis.
Journal: Breast cancer research and treatment
Published: July 25, 2025
Effectiveness and Safety of Sacituzumab Govitecan in Real-World Clinical Practice in Patients with Metastatic Triple-Negative and HR+/HER2-Negative Breast Cancer.
Journal: Biomedicines
Published: July 23, 2025
Sacituzumab govitecan in the first-line treatment of triple-negative breast cancer: balancing therapeutic sequencing with patient-relevant benefits.
Journal: The oncologist
Published: July 22, 2025
Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety.
Journal: Cancer chemotherapy and pharmacology
Published: July 17, 2025
Last Updated: 10/31/2025